Summary
Starting in July 1985, the Gynecologic Oncology Group conducted a series of phase II trials with ifosfamide/mesna in advanced or recurrent gynecologic malignancies. Previously untreated patients received 1.5 g/m2 i.v. ifosfamide daily for 5 days. Mesna was given i.v. q4h×3 following ifosfamide; each dose was 20% of the daily ifosfamide dose. All patients with ovarian and 87% of those with cervical cancer had previously undergone platinum-based therapy. Because of the toxicity encountered in previously treated patients with ovarian carcinoma, the dose of ifosfamide was reduced to 1.2 g/m2 daily in all patients who had received prior chemo- or radiotherapy. In epithelial ovarian carcinoma, responses were observed in 8 (20.0%) of 41 evaluable patiens, with 3 (7.0%) complete responses. Response duration was 2.1–20.3+ months, with a median of 6.9+ months. In squamous-cell carcinoma of the cervix, 3 (11.1%) of 27 evaluable patients showed partial responses of 1.8, 2.2, and 3.1 months' duration. Of 26 untreated patients with mixed mesodermal tumors of the uterus, 5 (19.2%) achieved complete and 3 (11.5%) showed partial responses, for an overall response rate of 30.7%. Response duration was 1.4+-8.6 months, with a median of 3.8 months. Toxicity included two deaths due to renal insufficiency and a third related to neurologic impairment. Hematologic toxicity was manageable. Ifosfamide/mesna has activity in a wide range of gynecologic malignancies.
Similar content being viewed by others
References
Beecham J, Blessing J, Creasman N (1988) Tamoxifen responsiveness, hormone receptors and tumor grade: a prospective study of 105 advanced ovarian cancer patients (abstract). Proceedings, Society of Gynecologic Oncology meeting February
Blessing JA (1984) Design, analysis and interpretation of chemotherapy trials in gynecologic cancer. In: G Deppe (ed) Chemotherapy of gynecologic cancer. AR Liss, New York, pp 49–83
Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verwey J, Dombernowsky P, Onsrud M, Thomas D, Sylvester R, van Oosterom A (1987) Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcoma. Eur J Cancer Clin Oncol 23:311–321
Bruehl P, Guenther U, Hoefer-Janker (1976) Results obtained with fractionated ifosfamide massive dose treatment in generalized malignant tumors. Int J Clin Pharmacol 14:29–30
Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ (1982) IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60: 693–697
Coleman RE, Harper PG, Gallagher C, Osborne R, Rankin EM, Silverstone AC, Slevin ML, Souhami RL, Tobias JS, Trask CW (1986) A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 18:280–283
Fossa SK, Talle K (1980) Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation. Cancer Treat Rep 64:1103–1108
Goren MP, Wright RK, Pratt CB, Pell FE (1986) Dechloroethylation of ifosfamide and neurotoxicity. Lancet II:1219–1220
Goren MP, Wright RK, Pratt CB, Horowitz ME, Dodge RK, Viar MJ, Kovnar EH (1987) Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by priorcis-diamminedichloroplatinum(II) therapy. Cancer Res 47:1457–1460
Homesley HD, Blessing JA, Berman M (1986) ICRF-159 (rozoxane) in patients with advanced nonsquamous cell carcinoma of the cervix. Am J Clin Oncol (CCT) 9:325–326
Lagasse L, Thigpen JT, Morrison F (1979) Phase II trial of piperazinedione in treatment of advanced endometrial carcinoma, uterine sarcoma, and vulvar carcinoma (abstract). Proc Am Soc Clin Oncol 400
Loehrer PJ, Williams SD, Einhorn LH, Ansari R (1985) Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas. J Clin Oncol 3:367–372
Omura GA, Major FJ, Blessing JA (1983) A randomized study of Adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52:626–632
Stehman FB, Blom J, Blessing J (1983) Phase II trial of galactitol 1,2: 5,6-dianhydro (NSC 132313) in the treatment of advanced gynecologic malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 15:381–390
Thigpen T, Lagasse L, Homesley H (1983) Cis-platinum in the treatment of advanced or recurrent adenocarcinoma of the ovary. Am J Clin Oncol (CCT) 6:431–435
Thigpen JT, Blessing JA, Orr JW, DiSaia PJ (1986) Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study. Cancer Treat Rep 70:271–274
Wheeler BM, Loehrer PJ, Williams SD Einhorn LH (1986) Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4:28–34
Yazigi R, Wild R, Madrid J, Arraztoa J (1984) Ifosfamide treatment of advanced ovarian cancer. Obstet Gynecol 63:163–166
Zalupski M, Baker LH (1988) Review: ifosfamide. J Natl Cancer Inst 80:556–566
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sutton, G.P., Blessing, J.A., Photopulos, G. et al. Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies. Cancer Chemother. Pharmacol. 26 (Suppl 1), S55–S58 (1990). https://doi.org/10.1007/BF00685421
Issue Date:
DOI: https://doi.org/10.1007/BF00685421